Opella

Paris – October 14, 2026 -- The share of patients reporting sleep difficulties fell by 59%, 56% and 55% within 48 hours of starting Mucosolvan or Bisolvon, according to a new real-world study from Opella on acute chesty cough.

Sleep complaints drop across three categories within 48 hours

The percentage of patients reporting difficulty falling asleep fell by 59%. Those reporting difficulty staying asleep fell by 56%, and those reporting sleep-related tiredness by 55%. Opella describes sleep disruption as a primary patient concern.

Social impact of cough improves meaningfully within 72 hours

Patients achieved a clinically meaningful improvement in the social impact of cough within 72 hours. Data also showed improvements in daily functioning from the first day of treatment.